By Lotus International

Understanding Weight Loss Drugs

With obesity rates soaring worldwide, pharmaceutical weight loss solutions have become a medical necessity — not luxury. Obesity contributes significantly to Type 2 diabetes, hypertension, cardiovascular disease, and certain cancers. Anti-obesity medications are designed to:
– Suppress appetite
– Inhibit fat absorption
– Modify metabolism
– Improve insulin sensitivity

Mechanisms of Action

1. Appetite suppression – GLP‑1 mimetics increase fullness
2. Delayed gastric emptying – Slows digestion, reducing food intake
3. Fat absorption blockers – Lipase inhibitors prevent dietary fats from absorbing
4. These drugs influence brain chemicals to curb hunger signals and reduce food cravings.

Drug Classes & Popular Brands

GLP-1 Agonists:
– Semaglutide (Ozempic, Wegovy / Semaglutide by Biocon etc.) – Once-weekly injection
– Liraglutide (Saxenda / Lirafit) – Once-daily injection

Lipase Inhibitors:
– Orlistat (Xenical / Orlistat by Cipla) – 120 mg, 3×/day with meals

CNS & Others:
– Phentermine + Topiramate ER (Qsymia) – Once daily (Not widely available in India)
– Bupropion + Naltrexone (Contrave) – Twice daily (Not available in India)

Emerging Dual Agonists:
– Tirzepatide (Mounjaro) – Once-weekly injection (in pipeline)

Dosage Timelines

– Semaglutide (Ozempic/Wegovy): Weekly
– Liraglutide (Saxenda): Daily
– Orlistat (Xenical): 3x per day with meals
– Qsymia / Contrave: Oral daily regimens

Efficacy Insights

– Semaglutide (Wegovy): ~15% of body weight — Now available in India from June 2025
– Liraglutide (Saxenda): 8–10% — Daily dosing required
– Orlistat: 5–7% — Mild, with gastrointestinal side effects
– Tirzepatide (Mounjaro): 20%+ — Emerging powerhouse

🌍 🇮🇳 India Welcomes Wegovy Launch in 2025
June 2025 marked the launch of Wegovy in India, as Novo Nordisk expanded its GLP-1 weight loss therapy to one of the world’s fastest-growing pharma markets.-

– 0.25 mg

– 0.50 mg

– 1.00 mg
– 1.75 mg
– 2.4 mg

It is the first high-dose GLP-1 injectable weight loss treatment now legally marketed in India. Commercial availability begins end of June.

Why Demand is Exploding

– GLP‑1 drugs not only reduce weight but also improve heart and metabolic health
– The global obesity drug market is projected to cross $150 billion by 2030

How We Source & Export from India

Lotus International partners with WHO‑GMP, US-FDA, and EU-GMP certified manufacturers to offer:
– Semaglutide and Liraglutide injectables
– Branded generics (Ozempic, Wegovy alternatives)
– Regulatory documentation: CoA, MSDS, invoice
– Cold-chain logistics for injectable medicines
– Custom packaging and private labeling

Import Weight Loss Drugs from India

If you’re sourcing for clinics, hospitals, pharmacies, or telehealth startups, we can help accelerate access to high-quality, effective weight management solutions.

Contact us
Email: [email protected]